Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? BIO’s Duncan Joins AAM

As Coherus Names New Chair Of Scientific Advisory Board

Executive Summary

The Association for Accessible Medicines has appointed former Biotechnology Innovation Organization representative Joanne Duncan as its new chief operating officer.  Meanwhile, Coherus has names the new chair of its scientific advisory board, while women’s health specialist Theramex has added to its board of directors

You may also be interested in...



AAM Applauds HHS For Acknowledging Brand-Driven Cost Increases

The AAM has applauded US proposals to lower drug prices, following the development of the HHS’s 45-day plan in response to president Joe Biden’s executive order on promoting competition. However, AAM chief executive Dan Leonard has criticized Congressional proposals to weaken the 180-day incentive for first generics and curtail patent settlement agreements as “misguided.”

Alkem Delivers Strong Quarter With Domestic Recovery

India’s Alkem has delivered a strong quarter with a boost in its domestic business on the back of “strong volume-led growth in the acute therapies and faster than market growth in chronic therapies.” However, the company saw a slight YoY decline in the US.

Lupin Strikes Deal For Anti-TB Drug Pretomanid

Lupin and non-profit organization TB Alliance have entered into a partnership for a new therapy for highly drug-resistant tuberculosis, pretomanid, to be distributed in 140 countries and territories.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel